What FTC substantiation for health claims actually requires
The FTC's standard for health-related marketing claims does not turn on intent to deceive. It asks whether, before the claim was made, the company already held competent and reliable scientific evidence to support it. The FTC's Health Products Compliance Guidance sets this standard for supplements, devices and other health products, and the same logic applies to marketing around biologics: the evidence has to exist first.
This standard reaches further than the literal words in an ad. A claim can be made through imagery, a headline next to a product photo, a hashtag, or the overall impression a reasonable viewer takes away, even if no single sentence states it outright. A page that pairs a condition name with a product listing, or a social post that implies a biologic was used to address a named condition, can create the same substantiation obligation as a direct written claim.
Why distributor and clinic claims both carry this obligation
Procurement teams sometimes assume that because they did not write the advertising copy, they are not responsible for it. The FTC has not treated that distinction as a shield. A distributor that supplies marketing language, a clinic that republishes it, and an affiliate that promotes it on commission can each be independently responsible for the claim as it appears to the public, because each party is disseminating it.
This matters specifically for biologics marketing, where the line between a factual, documentation-based statement, such as donor screening occurred, a lot carries a unique identifier, or a product shipped on dry ice, and an implied health claim, such as a condition name paired with a product or a testimonial describing relief, is where substantiation exposure concentrates. The first category describes operations. The second category requires evidence the FTC can ask to see.
What FDA's 2026 warning letters show about unsubstantiated claims
FDA's 2026 enforcement actions against distributors of private-label cord tissue and exosome products give a concrete picture of what regulators look at first: website language, social media posts, and affiliate content describing disease benefits. FDA cited exactly this kind of content as evidence of a product's intended use in warning letters to R3 Medical Companies, Blue Horizon International, and Dynamic Stem Cell Therapy.
FDA intended-use requirements and FTC substantiation requirements are separate; review both with counsel.
Testimonials and before-and-after content don't lower the bar
A patient testimonial describing improvement, or a before-and-after image pair, functions as a health claim even without a disease word in the copy; FTC guidance treats this content the same as a written claim, since the net impression controls regardless of any disclaimer in small type. Clinics and distributors should not rely on patient-submitted content, including social reposts, as marketing material unless it has gone through the same substantiation review as copy the company wrote itself.
Keeping a claims file: this is not legal advice
A practical first step is a written record of what evidence supports every health-adjacent claim a company makes or republishes, reviewed before the claim is published rather than after an inquiry arrives. That record should cover owned content, affiliate content, and reposted patient or customer content alike, since both FTC and FDA have treated third-party content promoted by a company as the company's own claim.
None of this is legal advice, and nothing in this article should be treated as a substitute for it. Clinics and distributors evaluating their own marketing should work with FDA and FTC regulatory counsel before publishing claims about biologic products, and should treat operational documentation, certificates of analysis, donor eligibility summaries, lot release records, as the category of material that can be shared, distinct from any claim about effect.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Does FTC substantiation apply to distributors, or only to clinics running their own ads?+
Both. Any party that makes or disseminates a claim can be independently responsible for it, so a clinic that repeats a distributor's marketing language assumes the same substantiation duty for that language.
Is a disclaimer like 'results not guaranteed' enough to satisfy the FTC?+
No. A disclaimer does not cure a lack of underlying evidence. The FTC looks at the net impression created by the whole ad, not at a single qualifying line.
Do patient testimonials substitute for scientific evidence?+
No. Testimonials describe one person's experience and are not competent and reliable scientific evidence under FTC guidance, even when they're accurate.
Who should review marketing copy before it goes live?+
Regulatory counsel familiar with both FTC substantiation standards and FDA rules for biologics, not general marketing counsel alone.